Background: Intravenous misuse and attention-deficit/hyperactivity disorder (ADHD) are common in patients under opioid maintenance treatment (OMT), who often misuse benzodiazepine (BZD). Objectives: To explore the rate of adult ADHD among patients under OMT in Italy and whether screening positive for adult ADHD is associated with OMT and BZD misuse and emergency room (ER) admission because of misuse. Methods: We recruited 1,649 patients from 27 addiction units (AUs) in Italy and collected data on the self-reported rate of OMT intravenous misuse (prevalence, repeated misuse, main reason, temporal pattern in relation to AU access, experience), concurrent intravenous and intranasal BZD misuse (prevalence, type of misused BZD), ADHD and ER admissions because of misuse complications. Results: Screening positive for adult ADHD was found in 11.2% patients (ADHD+), with a significant gender difference (women: 15.3%, men: 10.3%). OMT misuse was reported by 24.4 and 18.5% patients during lifetime and in the previous 6 months respectively. BZD misuse was reported by 20.0 and 8.6% patients for intravenous and intranasal route respectively. Misuse was significantly more common in ADHD+ (OMT 27.4–33.1%, BZD 14.5–31.5%) than ADHD– group (OMT 17.4–23.3%, BZD 7.9–18.3%). The multivariate logistic regression model showed positive screening for ADHD to be significantly associated with intravenous OMT misuse in the previous 6 months, and intravenous/intranasal BZD misuse, independently of age, gender and route of previous heroin administration. Conclusions: Screening positive for adult ADHD was associated with OMT and BZD misuse. AU physicians and medical personnel should focus on OMT patient’s features that are associated with a higher likelihood of misuse, in particular ADHD.

Keywords:
Adult attention deficit/hyperactivity disorder, Benzodiazepine, Compliance, Concomitant drug use, Italy, Misused medications, Opiate, Opioid maintenance , Overdoses, Population-based study
1.
Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo InterSERT di Collaborazione Scientifica (GICS). Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Eur Addict Res
. 2019;25(1):10–9.
2.
Bell J. Pharmacological maintenance treatments of opiate addiction.
Br J Clin Pharmacol
. 2014 Feb;77(2):253–63.
3.
Dale O, Hoffer C, Sheffels P, Kharasch ED. Disposition of nasal, intravenous, and oral methadone in healthy volunteers.
Clin Pharmacol Ther
. 2002 Nov;72(5):536–45.
4.
Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia.
Addiction
. 2003 Apr;98(4):413–8.
5.
Chevalley AE, Besson J, Croquette-Krokar M, Davidson C, Dubois JA, Uehlinger C, et al. Prevalence of methadone injection in three Swiss cities.
Presse Med
. 2005 Jun;34(11):776–80.
6.
Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment.
Drug Alcohol Depend
. 2007 Sep;90(1):64–71.
7.
Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Int J Drug Policy
. 2008 Dec;19(6):450–8.
8.
Maremmani I, Pacini M, Pani PP, Popovic D, Romano A, Maremmani AG, et al. Use of street methadone in italian heroin addicts presenting for opioid agonist treatment.
J Addict Dis
. 2009 Oct;28(4):382–8.
9.
Moratti E, Kashanpour H, Lombardelli T, Maisto M. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
Clin Drug Investig
. 2010;30 Suppl 1:3–11.
10.
Judson G, Bird R, O’Connor P, Bevin T, Loan R, Schroder M, et al. Drug injecting in patients in New Zealand Methadone Maintenance Treatment programs: an anonymous survey.
Drug Alcohol Rev
. 2010 Jan;29(1):41–6.
11.
Nordmann S, Frauger E, Pauly V, Orléans V, Pradel V, Mallaret M, et al. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.
Pharmacoepidemiol Drug Saf
. 2012 Feb;21(2):184–90.
12.
Bouquié R, Wainstein L, Pilet P, Mussini JM, Deslandes G, Clouet J, et al. Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions.
PLoS One
. 2014 Dec;9(12):e113991.
13.
Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008-2013.
Drug Alcohol Depend
. 2014 Sep;142:98–104.
14.
Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Addiction
. 2010 Apr;105(4):709–18.
15.
Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.
Subst Abuse Rehabil
. 2015 Jan;6:1–14.
16.
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
Am J Drug Alcohol Abuse
. 2009;35(2):68–72.
17.
Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Drug Alcohol Depend
. 2014 Mar;136:21–7.
18.
Weimer MB, Korthuis PT, Behonick GS, Wunsch MJ. The source of methadone in overdose deaths in Western Virginia in 2004.
J Addict Med
. 2011 Sep;5(3):188–202.
19.
Robinson GM, Kemp R, Lee C, Cranston D. Patients in methadone maintenance treatment who inject methadone syrup: a preliminary study.
Drug Alcohol Rev
. 2000 Dec;19(4):447–50.
20.
McBride AJ, Pates RM, Arnold K, Ball N. Needle fixation, the drug user’s perspective: a qualitative study.
Addiction
. 2001 Jul;96(7):1049–58.
21.
Chen KW, Berger CC, Forde DP, D’Adamo C, Weintraub E, Gandhi D. Benzodiazepine use and misuse among patients in a methadone program.
BMC Psychiatry
. 2011 May;11(1):90.
22.
Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature.
Eur Addict Res
. 2012;18(5):228–45.
23.
Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France.
Drug Alcohol Depend
. 2012 Nov;126(1-2):13–20.
24.
Bouvier BA, Waye KM, Elston B, Hadland SE, Green TC, Marshall BDL. Prevalence and correlates of benzodiazepine use and misuse among young adults who use prescription opioids non-medically.
Drug Alcohol Depend
. 2018 Feb;183:73–7.
25.
Herbert A, Gilbert R, Cottrell D, Li L. Causes of death up to 10 years after admissions to hospitals for self-inflicted, drug-related or alcohol-related, or violent injury during adolescence: a retrospective, nationwide, cohort study.
Lancet
. 2017 Aug;390(10094):577–87.
26.
Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.
BMJ
. 2017 Mar;356:j760.
27.
Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan.
Curr Opin Psychiatry
. 2007 Jul;20(4):386–92.
28.
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.
Am J Psychiatry
. 2006 Apr;163(4):716–23.
29.
Volkow ND, Swanson JM. Clinical practice: adult attention deficit-hyperactivity disorder.
N Engl J Med
. 2013 Nov;369(20):1935–44.
30.
Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.
Mol Psychiatry
. 2016 Jul;21(7):872–84.
31.
van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.
Drug Alcohol Depend
. 2012 Apr;122(1-2):11–9.
32.
van Emmerik-van Oortmerssen K, van de Glind G, Koeter MW, Allsop S, Auriacombe M, Barta C, et al.; IASP research group. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study.
Addiction
. 2014 Feb;109(2):262–72.
33.
van de Glind G, van den Brink W, Koeter MW, Carpentier PJ, van Emmerik-van Oortmerssen K, Kaye S, et al.; IASP Research Group. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients.
Drug Alcohol Depend
. 2013 Oct;132(3):587–96.
34.
van de Glind G, Konstenius M, Koeter MW, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, et al.; IASP Research Group. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria.
Drug Alcohol Depend
. 2014 Jan;134:158–66.
35.
Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.
J Am Acad Child Adolesc Psychiatry
. 2011 Jan;50(1):9–21.
36.
Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.
Clin Psychol Rev
. 2011 Apr;31(3):328–41.
37.
Carpentier PJ, van Gogh MT, Knapen LJ, Buitelaar JK, De Jong CA. Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients.
Eur Addict Res
. 2011;17(1):10–20.
38.
Lugoboni F, Levin FR, Pieri MC, Manfredini M, Zamboni L, Somaini L, et al.; Gruppo InterSert Collaborazione Scientifica Gics. Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: patients characteristics and treatment needs.
Psychiatry Res
. 2017 Apr;250:210–6.
39.
Peles E, Schreiber S, Sutzman A, Adelson M. Attention deficit hyperactivity disorder and obsessive-compulsive disorder among former heroin addicts currently in methadone maintenance treatment.
Psychopathology
. 2012;45(5):327–33.
40.
Fiksdal Abel K, Ravndal E, Clausen T, Bramness JG. Attention Deficit Hyperactivity Disorder Symptoms are Common in Patients in Opioid Maintenance Treatment.
Eur Addict Res
. 2017;23(6):298–305.
41.
Kolpe M, Carlson GA. Influence of attention-deficit/hyperactivity disorder symptoms on methadone treatment outcome.
Am J Addict
. 2007 Jan-Feb;16(1):46–8.
42.
Tamburin S, Federico A, Morbioli L, Faccini M, Casari R, Zamboni L, et al. Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients.
Am J Addict
. 2017 Sep;26(6):610–4.
43.
Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population.
Psychol Med
. 2005 Feb;35(2):245–56.
44.
American Psychiatric Association (APA).
Diagnostic and Statistical Manual of Mental Disorders
. 4th ed. Washington (DC): American Psychiatric Press; 2000.
45.
Launonen E, Wallace I, Kotovirta E, Alho H, Simojoki K. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients.
Drug Alcohol Depend
. 2016 May;162:227–35.
46.
Liao YT, Chen CY, Ng MH, Huang KY, Shao WC, Lin TY, et al. Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms.
Am J Addict
. 2017 Jan;26(1):26–33.
47.
Williamson D, Johnston C. Gender differences in adults with attention-deficit/hyperactivity disorder: A narrative review.
Clin Psychol Rev
. 2015 Aug;40:15–27.
48.
Carpentier PJ, Arias Vasquez A, Hoogman M, Onnink M, Kan CC, Kooij JJ, et al. Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: a pilot study of six candidate genes.
Eur Neuropsychopharmacol
. 2013 Jun;23(6):448–57.
49.
Wilson JJ. ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment.
Am J Addict
. 2007;16(Suppl 1):5–11.
50.
Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.
Drug Alcohol Depend
. 2017 May;174:58–64.
51.
Guerra P, Soto A, Carcas AJ, Sancho A, Cassinello A, Frias-Iniesta J. Comparison of Lormetazepam Solution and Capsules in Healthy Volunteers: Early Exposure and Drug Pharmacokinetics.
Clin Drug Investig
. 2002;22:859–66.
52.
Faccini M, Tamburin S, Casari R, Morbioli L, Lugoboni F. High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde.
Intern Emerg Med
. 2019 Nov;14(8):1271–8.
53.
West NA, Severtson SG, Green JL, Dart RC. Trends in abuse and misuse of prescription opioids among older adults.
Drug Alcohol Depend
. 2015 Apr;149:117–21.
54.
Dakwar E, Mahony A, Pavlicova M, Glass A, Brooks D, Mariani JJ, et al. The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders.
J Clin Psychiatry
. 2012 Nov;73(11):e1372–8.
55.
Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, et al.; ICASA consensus group. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.
Eur Addict Res
. 2018;24(1):43–51.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.